메뉴 건너뛰기




Volumn 38, Issue 10, 2014, Pages 1165-1172

Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia

Author keywords

11q deletion; 17p deletion; Allogeneic hematopoietic cell transplant; CLL; Genomic aberrations; Outcomes

Indexed keywords

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHIMERA; CHROMOSOME DELETION; CHROMOSOME DELETION 11Q; CHROMOSOME DELETION 17Q; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMORBIDITY; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LEUKEMIA REMISSION; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SURVIVAL PREDICTION; SURVIVAL TIME; 11Q DELETION; 17P DELETION; ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT; ALLOTRANSPLANTATION; CHROMOSOME 11; CHROMOSOME 17; CLL; DISEASE FREE SURVIVAL; GENE DELETION; GENETICS; GENOMIC ABERRATIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN GENOME; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OUTCOMES; PROGNOSIS; RETROSPECTIVE STUDY;

EID: 84907962686     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.04.006     Document Type: Article
Times cited : (12)

References (48)
  • 2
    • 83255170962 scopus 로고    scopus 로고
    • Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia
    • Carballido E., Veliz M., Komrokji R., Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control 2012, 19:54-67.
    • (2012) Cancer Control , vol.19 , pp. 54-67
    • Carballido, E.1    Veliz, M.2    Komrokji, R.3    Pinilla-Ibarz, J.4
  • 4
    • 23044501404 scopus 로고    scopus 로고
    • Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    • Wierda W., O'Brien S., Wen S., Faderl S., Garcia-Manero G., Thomas D., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070-4078.
    • (2005) J Clin Oncol , vol.23 , pp. 4070-4078
    • Wierda, W.1    O'Brien, S.2    Wen, S.3    Faderl, S.4    Garcia-Manero, G.5    Thomas, D.6
  • 5
    • 23044510136 scopus 로고    scopus 로고
    • Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
    • Keating M.J., O'Brien S., Albitar M., Lerner S., Plunkett W., Giles F., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079-4088.
    • (2005) J Clin Oncol , vol.23 , pp. 4079-4088
    • Keating, M.J.1    O'Brien, S.2    Albitar, M.3    Lerner, S.4    Plunkett, W.5    Giles, F.6
  • 6
    • 19944429446 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
    • Byrd J.C., Rai K., Peterson B.L., Appelbaum F.R., Morrison V.A., Kolitz J.E., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105:49-53.
    • (2005) Blood , vol.105 , pp. 49-53
    • Byrd, J.C.1    Rai, K.2    Peterson, B.L.3    Appelbaum, F.R.4    Morrison, V.A.5    Kolitz, J.E.6
  • 7
    • 0036139106 scopus 로고    scopus 로고
    • Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed
    • Keating M.J., Cazin B., Coutre S., Birhiray R., Kovacsovics T., Langer W., et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002, 20:205-213.
    • (2002) J Clin Oncol , vol.20 , pp. 205-213
    • Keating, M.J.1    Cazin, B.2    Coutre, S.3    Birhiray, R.4    Kovacsovics, T.5    Langer, W.6
  • 8
    • 84865997474 scopus 로고    scopus 로고
    • Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis
    • Kharfan-Dabaja M.A., Pidala J., Kumar A., Terasawa T., Djulbegovic B. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplant 2012, 47:1164-1170.
    • (2012) Bone Marrow Transplant , vol.47 , pp. 1164-1170
    • Kharfan-Dabaja, M.A.1    Pidala, J.2    Kumar, A.3    Terasawa, T.4    Djulbegovic, B.5
  • 9
    • 0025757084 scopus 로고
    • Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG
    • Michallet M., Corront B., Hollard D., Gratwohl A., Milpied N., Dauriac C., et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG. Bone Marrow Transplant 1991, 7:275-279.
    • (1991) Bone Marrow Transplant , vol.7 , pp. 275-279
    • Michallet, M.1    Corront, B.2    Hollard, D.3    Gratwohl, A.4    Milpied, N.5    Dauriac, C.6
  • 11
    • 27744580700 scopus 로고    scopus 로고
    • Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease
    • Toze C.L., Galal A., Barnett M.J., Shepherd J.D., Conneally E.A., Hogge D.E., et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 2005, 36:825-830.
    • (2005) Bone Marrow Transplant , vol.36 , pp. 825-830
    • Toze, C.L.1    Galal, A.2    Barnett, M.J.3    Shepherd, J.D.4    Conneally, E.A.5    Hogge, D.E.6
  • 12
    • 85014257001 scopus 로고    scopus 로고
    • Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia
    • Dreger P., Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002, 16:985-992.
    • (2002) Leukemia , vol.16 , pp. 985-992
    • Dreger, P.1    Montserrat, E.2
  • 13
    • 28844483804 scopus 로고    scopus 로고
    • Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
    • Gribben J.G., Zahrieh D., Stephans K., Bartlett-Pandite L., Alyea E.P., Fisher D.C., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005, 106:4389-4396.
    • (2005) Blood , vol.106 , pp. 4389-4396
    • Gribben, J.G.1    Zahrieh, D.2    Stephans, K.3    Bartlett-Pandite, L.4    Alyea, E.P.5    Fisher, D.C.6
  • 14
    • 84877282791 scopus 로고    scopus 로고
    • Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies
    • El-Jurdi N., Reljic T., Kumar A., Pidala J., Bazarbachi A., Djulbegovic B., et al. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy 2013, 5:457-466.
    • (2013) Immunotherapy , vol.5 , pp. 457-466
    • El-Jurdi, N.1    Reljic, T.2    Kumar, A.3    Pidala, J.4    Bazarbachi, A.5    Djulbegovic, B.6
  • 15
    • 0031879197 scopus 로고    scopus 로고
    • Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
    • Khouri I.F., Keating M., Korbling M., Przepiorka D., Anderlini P., O'Brien S., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-2824.
    • (1998) J Clin Oncol , vol.16 , pp. 2817-2824
    • Khouri, I.F.1    Keating, M.2    Korbling, M.3    Przepiorka, D.4    Anderlini, P.5    O'Brien, S.6
  • 16
    • 55549097826 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis
    • Schetelig J., van Biezen A., Brand R., Caballero D., Martino R., Itala M., et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008, 26:5094-5100.
    • (2008) J Clin Oncol , vol.26 , pp. 5094-5100
    • Schetelig, J.1    van Biezen, A.2    Brand, R.3    Caballero, D.4    Martino, R.5    Itala, M.6
  • 17
    • 54449093967 scopus 로고    scopus 로고
    • Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    • Sorror M.L., Storer B.E., Sandmaier B.M., Maris M., Shizuru J., Maziarz R., et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008, 26:4912-4920.
    • (2008) J Clin Oncol , vol.26 , pp. 4912-4920
    • Sorror, M.L.1    Storer, B.E.2    Sandmaier, B.M.3    Maris, M.4    Shizuru, J.5    Maziarz, R.6
  • 18
    • 20844436596 scopus 로고    scopus 로고
    • Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis
    • Dreger P., Brand R., Milligan D., Corradini P., Finke J., Lambertenghi Deliliers G., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005, 19:1029-1033.
    • (2005) Leukemia , vol.19 , pp. 1029-1033
    • Dreger, P.1    Brand, R.2    Milligan, D.3    Corradini, P.4    Finke, J.5    Lambertenghi Deliliers, G.6
  • 19
    • 83255164801 scopus 로고    scopus 로고
    • Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens
    • Kharfan-Dabaja M.A., Bazarbachi A. Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. Cancer Control 2012, 19:68-75.
    • (2012) Cancer Control , vol.19 , pp. 68-75
    • Kharfan-Dabaja, M.A.1    Bazarbachi, A.2
  • 20
    • 52049122208 scopus 로고    scopus 로고
    • Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia
    • Kharfan-Dabaja M.A., Chavez J.C., Khorfan K.A., Pinilla-Ibarz J. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer 2008, 113:897-906.
    • (2008) Cancer , vol.113 , pp. 897-906
    • Kharfan-Dabaja, M.A.1    Chavez, J.C.2    Khorfan, K.A.3    Pinilla-Ibarz, J.4
  • 21
    • 45149100665 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
    • Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
    • (2008) Blood , vol.111 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3    Caligaris-Cappio, F.4    Dighiero, G.5    Dohner, H.6
  • 22
    • 33845543049 scopus 로고    scopus 로고
    • Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
    • Dreger P., Corradini P., Kimby E., Michallet M., Milligan D., Schetelig J., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12-17.
    • (2007) Leukemia , vol.21 , pp. 12-17
    • Dreger, P.1    Corradini, P.2    Kimby, E.3    Michallet, M.4    Milligan, D.5    Schetelig, J.6
  • 23
    • 77957664665 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
    • Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
    • (2010) Lancet , vol.376 , pp. 1164-1174
    • Hallek, M.1    Fischer, K.2    Fingerle-Rowson, G.3    Fink, A.M.4    Busch, R.5    Mayer, J.6
  • 24
    • 77953556313 scopus 로고    scopus 로고
    • A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis
    • Perkins J., Field T., Kim J., Kharfan-Dabaja M.A., Fernandez H., Ayala E., et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010, 16:937-947.
    • (2010) Biol Blood Marrow Transplant , vol.16 , pp. 937-947
    • Perkins, J.1    Field, T.2    Kim, J.3    Kharfan-Dabaja, M.A.4    Fernandez, H.5    Ayala, E.6
  • 25
    • 84870455529 scopus 로고    scopus 로고
    • A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation
    • Pidala J., Kim J., Jim H., Kharfan-Dabaja M.A., Nishihori T., Fernandez H., et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012, 97:1882-1889.
    • (2012) Haematologica , vol.97 , pp. 1882-1889
    • Pidala, J.1    Kim, J.2    Jim, H.3    Kharfan-Dabaja, M.A.4    Nishihori, T.5    Fernandez, H.6
  • 27
    • 23944440464 scopus 로고    scopus 로고
    • Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
    • Sorror M.L., Maris M.B., Storb R., Baron F., Sandmaier B.M., Maloney D.G., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
    • (2005) Blood , vol.106 , pp. 2912-2919
    • Sorror, M.L.1    Maris, M.B.2    Storb, R.3    Baron, F.4    Sandmaier, B.M.5    Maloney, D.G.6
  • 31
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 32
    • 0000120995 scopus 로고
    • A class of K-sample tests for comparing the cumulative incidence of a competing risk
    • Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
    • (1988) Ann Stat , vol.16 , pp. 1141-1154
    • Gray, R.J.1
  • 33
    • 1542532754 scopus 로고    scopus 로고
    • A proportional hazards model for the subdistribution of a competing risk
    • Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
    • (1999) J Am Stat Assoc , vol.94 , pp. 496-509
    • Fine, J.P.1    Gray, R.J.2
  • 35
    • 35548984981 scopus 로고    scopus 로고
    • Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
    • Brunstein C.G., Barker J.N., Weisdorf D.J., DeFor T.E., Miller J.S., Blazar B.R., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
    • (2007) Blood , vol.110 , pp. 3064-3070
    • Brunstein, C.G.1    Barker, J.N.2    Weisdorf, D.J.3    DeFor, T.E.4    Miller, J.S.5    Blazar, B.R.6
  • 36
    • 0033008061 scopus 로고    scopus 로고
    • Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection
    • Thiede C., Florek M., Bornhauser M., Ritter M., Mohr B., Brendel C., et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999, 23:1055-1060.
    • (1999) Bone Marrow Transplant , vol.23 , pp. 1055-1060
    • Thiede, C.1    Florek, M.2    Bornhauser, M.3    Ritter, M.4    Mohr, B.5    Brendel, C.6
  • 37
    • 77957743452 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
    • Dreger P., Dohner H., Ritgen M., Bottcher S., Busch R., Dietrich S., et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010, 116:2438-2447.
    • (2010) Blood , vol.116 , pp. 2438-2447
    • Dreger, P.1    Dohner, H.2    Ritgen, M.3    Bottcher, S.4    Busch, R.5    Dietrich, S.6
  • 38
    • 84873567955 scopus 로고    scopus 로고
    • Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome
    • Brown J.R., Kim H.T., Armand P., Cutler C., Fisher D.C., Ho V., et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 2013, 27:362-369.
    • (2013) Leukemia , vol.27 , pp. 362-369
    • Brown, J.R.1    Kim, H.T.2    Armand, P.3    Cutler, C.4    Fisher, D.C.5    Ho, V.6
  • 39
    • 80053901737 scopus 로고    scopus 로고
    • Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome
    • Khouri I.F., Bassett R., Poindexter N., O'Brien S., Bueso-Ramos C.E., Hsu Y., et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011, 117:4679-4688.
    • (2011) Cancer , vol.117 , pp. 4679-4688
    • Khouri, I.F.1    Bassett, R.2    Poindexter, N.3    O'Brien, S.4    Bueso-Ramos, C.E.5    Hsu, Y.6
  • 40
    • 33947312235 scopus 로고    scopus 로고
    • Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
    • Brown J.R., Kim H.T., Li S., Stephans K., Fisher D.C., Cutler C., et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006, 12:1056-1064.
    • (2006) Biol Blood Marrow Transplant , vol.12 , pp. 1056-1064
    • Brown, J.R.1    Kim, H.T.2    Li, S.3    Stephans, K.4    Fisher, D.C.5    Cutler, C.6
  • 41
    • 27744549869 scopus 로고    scopus 로고
    • Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)
    • Caballero D., Garcia-Marco J.A., Martino R., Mateos V., Ribera J.M., Sarra J., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 2005, 11:7757-7763.
    • (2005) Clin Cancer Res , vol.11 , pp. 7757-7763
    • Caballero, D.1    Garcia-Marco, J.A.2    Martino, R.3    Mateos, V.4    Ribera, J.M.5    Sarra, J.6
  • 42
    • 84866334906 scopus 로고    scopus 로고
    • Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia
    • Jaglowski S.M., Ruppert A.S., Heerema N.A., Bingman A., Flynn J.M., Grever M.R., et al. Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. Br J Haematol 2012, 159:82-87.
    • (2012) Br J Haematol , vol.159 , pp. 82-87
    • Jaglowski, S.M.1    Ruppert, A.S.2    Heerema, N.A.3    Bingman, A.4    Flynn, J.M.5    Grever, M.R.6
  • 43
    • 84863468105 scopus 로고    scopus 로고
    • Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort
    • Toze C.L., Dalal C.B., Nevill T.J., Gillan T.L., Abou Mourad Y.R., Barnett M.J., et al. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol 2012, 158:174-185.
    • (2012) Br J Haematol , vol.158 , pp. 174-185
    • Toze, C.L.1    Dalal, C.B.2    Nevill, T.J.3    Gillan, T.L.4    Abou Mourad, Y.R.5    Barnett, M.J.6
  • 44
    • 79960036578 scopus 로고    scopus 로고
    • Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
    • Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
    • (2011) Nature , vol.475 , pp. 101-105
    • Puente, X.S.1    Pinyol, M.2    Quesada, V.3    Conde, L.4    Ordonez, G.R.5    Villamor, N.6
  • 45
    • 84879173666 scopus 로고    scopus 로고
    • TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
    • Dreger P., Schnaiter A., Zenz T., Bottcher S., Rossi M., Paschka P., et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 2013, 121:3284-3288.
    • (2013) Blood , vol.121 , pp. 3284-3288
    • Dreger, P.1    Schnaiter, A.2    Zenz, T.3    Bottcher, S.4    Rossi, M.5    Paschka, P.6
  • 46
    • 63749116929 scopus 로고    scopus 로고
    • Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes
    • van Besien K., Kunavakkam R., Rondon G., De Lima M., Artz A., Oran B., et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009, 15:610-617.
    • (2009) Biol Blood Marrow Transplant , vol.15 , pp. 610-617
    • van Besien, K.1    Kunavakkam, R.2    Rondon, G.3    De Lima, M.4    Artz, A.5    Oran, B.6
  • 47
    • 20544465644 scopus 로고    scopus 로고
    • Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia
    • Sorror M.L., Maris M.B., Sandmaier B.M., Storer B.E., Stuart M.J., Hegenbart U., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005, 23:3819-3829.
    • (2005) J Clin Oncol , vol.23 , pp. 3819-3829
    • Sorror, M.L.1    Maris, M.B.2    Sandmaier, B.M.3    Storer, B.E.4    Stuart, M.J.5    Hegenbart, U.6
  • 48
    • 38049141530 scopus 로고    scopus 로고
    • Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
    • Sorror M.L., Storer B.E., Maloney D.G., Sandmaier B.M., Martin P.J., Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008, 111:446-452.
    • (2008) Blood , vol.111 , pp. 446-452
    • Sorror, M.L.1    Storer, B.E.2    Maloney, D.G.3    Sandmaier, B.M.4    Martin, P.J.5    Storb, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.